Literature DB >> 15381811

Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease.

Elena Sbrana1, Shu-Yuan Xiao, Hilda Guzman, Mengyi Ye, Amelia P A Travassos da Rosa, Robert B Tesh.   

Abstract

Ribavirin was evaluated as a potential treatment of yellow fever (YF) in a hamster model of the disease. Ribavirin treatment during the first five days after YF virus infection improved survival, reduced tissue damage in target organs (liver and spleen), prevented hepatocellular steatosis, and normalized alanine aminotransferase levels. The results of this study suggest that ribavirin may be effective in the early treatment of YF, and that its mechanism of action in reducing liver pathology in YF virus infection may be similar to that observed with ribavirin in the treatment of chronic hepatitis C virus infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15381811

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential.

Authors:  Michael Zasloff; A Paige Adams; Bernard Beckerman; Ann Campbell; Ziying Han; Erik Luijten; Isaura Meza; Justin Julander; Abhijit Mishra; Wei Qu; John M Taylor; Scott C Weaver; Gerard C L Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.

Authors:  Justin G Julander; Shanta Bantia; Brian R Taubenheim; Dena M Minning; Pravin Kotian; John D Morrey; Donald F Smee; William P Sheridan; Yarlagadda S Babu
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.

Authors:  Eloise Mastrangelo; Margherita Pezzullo; Tine De Burghgraeve; Suzanne Kaptein; Boris Pastorino; Kai Dallmeier; Xavier de Lamballerie; Johan Neyts; Alicia M Hanson; David N Frick; Martino Bolognesi; Mario Milani
Journal:  J Antimicrob Chemother       Date:  2012-04-25       Impact factor: 5.790

4.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

5.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

Review 6.  Experimental therapies for yellow fever.

Authors:  Justin G Julander
Journal:  Antiviral Res       Date:  2012-12-10       Impact factor: 5.970

7.  Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection.

Authors:  M C Georges-Courbot; H Contamin; C Faure; P Loth; S Baize; P Leyssen; J Neyts; V Deubel
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

8.  Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model.

Authors:  Justin G Julander; John D Morrey; Lawrence M Blatt; Kristiina Shafer; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-09-22       Impact factor: 5.970

9.  Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.

Authors:  Justin G Julander; Kristiina Shafer; Donald F Smee; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes.

Authors:  Guangyu Li; Tao Duan; Xiaoyan Wu; Robert B Tesh; Lynn Soong; Shu-Yuan Xiao
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.